Inbrx-101/rhaat-fc    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
231Alpha-1-antitrypsin deficiency1

231. Alpha-1-antitrypsin deficiency    [ 83 clinical trials,   89 drugs,   (DrugBank: 16 drugs),   35 drug target genes,   46 drug target pathways]
Searched query = "Alpha-1-antitrypsin deficiency", "AATD"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 83 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03815396
(ClinicalTrials.gov)
July 19, 201921/1/2019Phase 1 Study to Assess the Safety, PK and PD of INBRX-101 in Adults With Alpha-1 Antitrypsin DeficiencyAn Open-Label, Multicenter, Phase 1 Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Intravenous Doses of Inhibrx rhAAT-Fc (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency (AATD)Alpha-1 Antitrypsin Deficiency;AATDDrug: INBRX-101/rhAAT-FcInhibrx, Inc.NULLRecruiting18 Years80 YearsAll30Phase 1United States;New Zealand;United Kingdom